161 related articles for article (PubMed ID: 19808976)
21. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
22. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
23. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
24. Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo.
Lei G; Xu M; Xu Z; Lu C; Tan S
Biomed Pharmacother; 2018 Feb; 98():271-279. PubMed ID: 29272788
[TBL] [Abstract][Full Text] [Related]
25. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models.
Hsu YH; Hsing CH; Li CF; Chan CH; Chang MC; Yan JJ; Chang MS
J Immunol; 2012 Feb; 188(4):1981-91. PubMed ID: 22238453
[TBL] [Abstract][Full Text] [Related]
26. 2-methoxyestradiol analogue ENMD-1198 reduces breast cancer-induced osteolysis and tumor burden both in vitro and in vivo.
Snoeks TJ; Mol IM; Que I; Kaijzel EL; Löwik CW
Mol Cancer Ther; 2011 May; 10(5):874-82. PubMed ID: 21422268
[TBL] [Abstract][Full Text] [Related]
27. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
[TBL] [Abstract][Full Text] [Related]
28. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
[TBL] [Abstract][Full Text] [Related]
29. Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein.
Bäuerle T; Peterschmitt J; Hilbig H; Kiessling F; Armbruster FP; Berger MR
Int J Oncol; 2006 Mar; 28(3):573-83. PubMed ID: 16465361
[TBL] [Abstract][Full Text] [Related]
30. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
[TBL] [Abstract][Full Text] [Related]
31. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
32. In vivo tibial compression decreases osteolysis and tumor formation in a human metastatic breast cancer model.
Lynch ME; Brooks D; Mohanan S; Lee MJ; Polamraju P; Dent K; Bonassar LJ; van der Meulen MC; Fischbach C
J Bone Miner Res; 2013 Nov; 28(11):2357-67. PubMed ID: 23649605
[TBL] [Abstract][Full Text] [Related]
33. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
34. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
[TBL] [Abstract][Full Text] [Related]
35. Sulforaphane inhibits the growth of KPL-1 human breast cancer cells in vitro and suppresses the growth and metastasis of orthotopically transplanted KPL-1 cells in female athymic mice.
Kanematsu S; Yoshizawa K; Uehara N; Miki H; Sasaki T; Kuro M; Lai YC; Kimura A; Yuri T; Tsubura A
Oncol Rep; 2011 Sep; 26(3):603-8. PubMed ID: 21617865
[TBL] [Abstract][Full Text] [Related]
36. APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.
Al-Ejeh F; Darby JM; Tsopelas C; Smyth D; Manavis J; Brown MP
PLoS One; 2009; 4(2):e4558. PubMed ID: 19247492
[TBL] [Abstract][Full Text] [Related]
37. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.
Fu M; Maresh EL; Helguera GF; Kiyohara M; Qin Y; Ashki N; Daniels-Wells TR; Aziz N; Gordon LK; Braun J; Elshimali Y; Soslow RA; Penichet ML; Goodglick L; Wadehra M
Mol Cancer Ther; 2014 Apr; 13(4):902-15. PubMed ID: 24448822
[TBL] [Abstract][Full Text] [Related]
38. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
[TBL] [Abstract][Full Text] [Related]
39. Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling.
Park SK; Sanders BG; Kline K
Breast Cancer Res Treat; 2010 Nov; 124(2):361-75. PubMed ID: 20157774
[TBL] [Abstract][Full Text] [Related]
40. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
